BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

Phase 2

Completed

Conditions: Thrombosis

Interventions: Drug: Aspirin
Drug: BMS-986141
Other: Placebo

First Posted Date: 2016-02-02

Last Posted Date: 2018-12-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16

Registration Number: NCT02671461

Locations: 🇺🇸
York Hospital, York, Pennsylvania, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 20 locations

An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

Phase 3

Completed

Conditions: Brain Neoplasms

Interventions: Drug: Nivolumab
Drug: Temozolomide
Radiation: Radiotherapy
Other: Nivolumab Placebo

First Posted Date: 2016-01-29

Last Posted Date: 2024-05-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 716

Registration Number: NCT02667587

Locations: 🇺🇸
Local Institution - 0028, Boston, Massachusetts, United States
🇺🇸
Local Institution - 0010, Los Angeles, California, United States
🇺🇸
Local Institution - 0128, Sacramento, California, United States

and more 120 locations

Clinical and Economic Burden of Bleeding Events in Patients in the UK With Non-valvular Atrial Fibrillation Treated With Vitamin k Antagonists

Completed

Conditions: Atrial Fibrillation

First Posted Date: 2016-01-22

Last Posted Date: 2016-01-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 16513

Registration Number: NCT02661516

Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES)

Completed

Conditions: Venous Thromboembolism

First Posted Date: 2016-01-22

Last Posted Date: 2016-01-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 38409

Registration Number: NCT02661568

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Phase 1

Completed

Conditions: Melanoma
Non-Small Cell Lung Cancer
Advanced Cancer

Interventions: Drug: BMS-986205
Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2016-01-20

Last Posted Date: 2023-08-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 627

Registration Number: NCT02658890

Locations: 🇺🇸
Local Institution - 0057, Pittsburgh, Pennsylvania, United States
🇫🇷
Local Institution - 0022, Villejuif, France
🇺🇸
Local Institution - 0033, Hackensack, New Jersey, United States

and more 44 locations

Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small-Cell Lung Cancer

Interventions: Biological: Nivolumab
Biological: Ipilimumab
Drug: Platinum Doublet Chemotherapy

First Posted Date: 2016-01-20

Last Posted Date: 2023-04-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 324

Registration Number: NCT02659059

Locations: 🇺🇸
Local Institution - 0010, Mineola, New York, United States
🇨🇦
Local Institution - 0022, Kingston, Ontario, Canada
🇺🇸
Local Institution - 0015, Lincoln, Nebraska, United States

and more 29 locations

An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2016-01-13

Last Posted Date: 2022-11-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 117

Registration Number: NCT02654132

Locations: 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States

and more 41 locations

Diclofenac 25mg/Paracetamol 500 mg and Diclofenac 50 mg/Paracetamol 500 mg for Patients With Pain

Completed

Conditions: Pain

First Posted Date: 2016-01-11

Last Posted Date: 2017-04-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 374

Registration Number: NCT02651363

Locations: 🇵🇪
Local Institution, San Miguel, Lima, Peru

APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study

Completed

Conditions: Anticoagulation

Interventions: Drug: dabigatran
Drug: VKA
Drug: Apixaban
Drug: rivaroxaban

First Posted Date: 2015-12-28

Last Posted Date: 2022-05-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 321501

Registration Number: NCT02640222

Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: BMS-986142
Drug: Placebo
Drug: Methotrexate

First Posted Date: 2015-12-23

Last Posted Date: 2019-05-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 508

Registration Number: NCT02638948

Locations: 🇺🇸
Precision Research Organization, Miami Lakes, Florida, United States
🇺🇸
Vizae Clinical Trials Management, Pembroke Pines, Florida, United States
🇺🇸
Integral Rheumatology & Immunology Specialists, Plantation, Florida, United States

and more 42 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy